Cypator

CypatorCypator
Cypator

Cypator

Liquidity-as-a-Service platform for institutional digital asset trading.

DR 112022Active6Tel Aviv, Israel
Rate

About

Cypator provides institutional crypto OTC and ECN trading solutions, offering real-time, scalable, and fully branded trading infrastructure. Their core products include a white-label Execution Management Solution for OTC desks and an ECN access platform connecting institutions to over 20 liquidity providers. Cypator serves OTC desks and institutions looking to trade digital assets with enhanced efficiency and reduced operational complexity.
Frequently asked

What does Cypator do?

Cypator provides institutional crypto OTC and ECN trading solutions, offering real-time, scalable, and fully branded trading infrastructure. Their core products include a white-label Execution Management Solution for OTC desks and an ECN access platform connecting institutions to over 20 liquidity providers. Cypator serves OTC desks and institutions looking to trade digital assets with enhanced efficiency and reduced operational complexity.

What is Cypator's revenue?

StartupHub estimates Cypator's annual revenue at $1.6M (range $968K to $3.1M, 64% confidence), based on comparable companies in the sector.

Where is Cypator headquartered?

Cypator is headquartered in Tel Aviv, Israel.

When was Cypator founded?

Cypator was founded in 2022.

What industry does Cypator operate in?

Cypator operates in Fintech, Web3, Crypto Exchange, Liquidity Solutions, Institutional Trading, Digital Assets.

How many employees does Cypator have?

Cypator has approximately 6 people on record.

HEADCOUNT
6
DOMAIN RATING
11
New entrants in Web3
Last 90 days
240
New entrants
80.0
Per month
18.7
Per week

An entrant is a company tagged Web3 whose domain was first registered in the window, counted from registry records in the StartupHub directory. 8 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.

Comments

No comments yet. Be the first to share your take.